GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

AIC499   Click here for help

GtoPdb Ligand ID: 14526

PDB Ligand
Compound class: Synthetic organic
Comment: AIC499 is a monocyclic β-lactam (monobactam) antibacterial that inhibits the penicillin-binding proteins of Gram-negative bacteria and demonstrates excellent activity against Gram-negative pathogens, including multi-drug resistant (MDR) clinical isolates [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 14
Hydrogen bond donors 7
Rotatable bonds 17
Topological polar surface area 312.39
Molecular weight 670.72
XLogP -1.06
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)([C@@H](C=O)NC(=O)/C(=N\O[C@@H](COC1=CC=C(C=C1)C(=N[C@@H]2CCCNC2)N)C(=O)O)/C3=CSC(=N3)N)NOS(=O)(=O)O
Isomeric SMILES CC(C)([C@@H](C=O)NC(=O)/C(=N\O[C@@H](COC1=CC=C(C=C1)C(=N[C@@H]2CCCNC2)N)C(=O)O)/C3=CSC(=N3)N)NOS(=O)(=O)O
InChI InChI=1S/C25H34N8O10S2/c1-25(2,33-43-45(38,39)40)19(11-34)31-22(35)20(17-13-44-24(27)30-17)32-42-18(23(36)37)12-41-16-7-5-14(6-8-16)21(26)29-15-4-3-9-28-10-15/h5-8,11,13,15,18-19,28,33H,3-4,9-10,12H2,1-2H3,(H2,26,29)(H2,27,30)(H,31,35)(H,36,37)(H,38,39,40)/b32-20-/t15-,18+,19-/m1/s1
InChI Key NFNVPYWCKFTXAX-OOLKDPNPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
AIC499 was developed by Aicuris (Germany) as a treatment for complicated urinary tract infections (cUTIs) and intra-abdominal infections (cIAis) caused by MDR Gram-negative bacteria. A Phase 1 clinical trial to evaluate the safety of AIC499 in healthy volunteers began in 2017, with Phase 2 studies planned. The results from these studies are unpublished, and AIC499 was removed from Aicuris's pipeline in 2019 for undisclosed reasons [2].